Open account
Sign up/Log in
UPDATE 1-Gilead posts quarterly loss on acquisition charge, revenue rises 5%
Gilead Sciences posts quarterly loss on acquisition charge, revenue rises 5% on higher HIV, oncology and liver disease treatment sales. Company took $3.9 billion charge for recent acquisition of liver drug developer CymaBay Therapeutics. Shares of Gilead were up 3.3% in after hours trading.
Reuters · 3d ago
Gilead posts quarterly loss, revenue rises 5%
Gilead posts quarterly loss, revenue rises 5% on higher HIV, oncology and liver disease treatment sales. Gilead took a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics. The company's first-quarter revenue rose 5% to $6.69 billion.
Reuters · 3d ago
UPDATE 4-Lazard profit beats estimates as dealmaking rebound fuels record revenue
Lazard's first-quarter profit beats estimates as dealmaking rebound fuels record revenue. Firmwide and advisory revenues surged to record levels. The bank advised on a string of high-profile deals in the first quarter. Lazard's adjusted revenue jumped 42% to $747 million.
Reuters · 3d ago
UPDATE 3-Lazard posts better-than-expected profit on deals, assets boost
Lazard posts better-than-expected profit on deals, assets boost in first quarter. Investment bank's adjusted revenue jumped 42% to $747 million. Firm advised on a string of high-profile mergers and acquisitions in the quarter. Lazard's assets under management rose to $250 billion from $232 billion.
Reuters · 3d ago
UPDATE 2-Lazard posts first-quarter profit on deals, assets boost
Lazard posts first-quarter profit on deals, assets boost. Investment bank's profit boosted by a string of high-profile mergers and acquisitions it advised on in the first quarter. Lazard's assets under management rose to $250 billion in the quarter from $232 billion a year earlier.
Reuters · 3d ago
Weekly Report: what happened at CBAY last week (0318-0322)?
Weekly Report · 03/25 09:10
Cymabay Therapeu: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 03/23 00:25
Cymabay Therapeu: Statement of changes in beneficial ownership of securities
Press release · 03/23 00:25
Webull offers Cymabay Therapeu stock information, including NASDAQ: CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.